<a href="https://laohu8.com/S/IMAB">I-Mab</a> Announces Promising Phase 1b Trial Results for Givastomig in Combination with Immunochemotherapy for Gastric Cancer at ESMO GI 2025
I-Mab, a global biotech company, has announced positive results from a Phase 1b dose escalation study of their novel drug, givastomig, combined with immunochemotherapy in patients with first-line gastric cancers. The study reported a 71% objective response rate $(ORR.AU)$ among participants, with an 83% ORR in patients across doses selected for an ongoing dose expansion study. The trial, which enrolled patients in the U.S., focused on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig in combination with nivolumab and mFOLFOX6. The primary endpoint of safety showed no dose limiting toxicities, and a maximum tolerated dose was not reached. Common treatment-related adverse events were generally mild to moderate. These findings are set to be presented at the ESMO Gastrointestinal Cancers Congress 2025 on July 2nd. I-Mab has scheduled an investor event on July 8th to further discuss the results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-090160), on June 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.